Precision Neuroscience raises $250M for brain-computer interface push
What's the deal? Precision Neuroscience, a New York-based startup building minimally invasive brain-computer interfaces, has raised $250 million in late-stage funding. The round drew in billionaire hedge fund manager Bill AckmanDealroom has a profile for this one. Try Dealroom →, placing him alongside Elon Musk and Jeff Bezos as backers in the sector.
What's the endgame? Founded in 2021 by Benjamin Rapoport and Michael Mager, Precision makes the Layer 7 Cortical Interface — a thin-film electrode array that rests on the brain's surface rather than being implanted inside it. The device won FDA 510(k) clearance in April 2025 for temporary use of up to 30 days.
The traction: Precision has run procedures on dozens of patients, building a dataset few rivals outside Neuralink can match. In January 2026, it partnered with MedtronicDealroom has a profile for this one. Try Dealroom →, the $110B medical device maker, to integrate its array with surgical navigation systems.
Why Ackman got involved: His involvement is personal. After his daughter suffered a brain hemorrhage, the Pershing SquareDealroom has a profile for this one. Try Dealroom → founder moved into neuroscience funding, and he and his wife set up the Ackman Oxman InstituteDealroom has a profile for this one. Try Dealroom →, a nonprofit for brain research, with an initial commitment of roughly $400 million.
By the numbers: The raise builds on a December 2024 Series C of $102 million at a post-money valuation of about $500 million. Total disclosed funding now sits well above the $180 million previously raised.
The competitive landscape: Neuralink, Musk's venture, threads electrodes directly into brain tissue using a surgical robot. Synchron, backed by Bezos, delivers its Stentrode device through blood vessels, avoiding open brain surgery entirely.
The signal: The round ranks near the 98th percentile by size among US late-stage health deals, a sign that brain-computer interfaces are moving from science fiction to serious capital. Big-name backers are now spreading their bets across competing surgical approaches.
Read more: cryptobriefing.com
Image credit: Precision Neuroscience
